Cargando…

HGG-23. IN VITRO AND IN VIVO PRECLINICAL DRUG SCREENING OF PROMISING THERAPEUTICS FOR DIFFUSE MIDLINE GLIOMA (DMG)

INTRODUCTION: Diffuse midline gliomas (DMGs) are amongst the most unforgiving pediatric brain tumors, characterized by an intrinsic resistance to therapy. Despite major advances in understanding of tumor biology, the prognosis remains exceedingly poor, and treatment options are limited. New therapeu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cosentino, Chiara Cianciolo, Laternser, Sandra, Przystal, Justyna M, Yadavilli, Sridevi, Zhang, Jie, Müller, Timothy, Kritzer, Bettina, Müller, Sabine, Nazarian, Javad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	High Grade Gliomas
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8263150/ http://dx.doi.org/10.1093/neuonc/noab090.087

Ejemplares similares

HGG-24. PRECLINICAL EFFICACY OF THE BRAIN PENETRANT CYCLIN-DEPENDENT KINASE INHIBITOR ZOTIRACICLIB IN PEDIATRIC DIFFUSE MIDLINE GLIOMAS
por: Mueller, Timothy, et al.
Publicado: (2021)

HGG-36. HIF-2: A NEW DRUG TARGET IN PEDIATRIC HIGH-GRADE GLIOMA WITH PROMISING PRECLINICAL RESULTS
por: Fuchs, Quentin, et al.
Publicado: (2020)

HGG-45. Characterization of spinal diffuse midline gliomas, H3 K28M-mutant
por: Stegat, Lotte, et al.
Publicado: (2022)

HGG-15. THE IMIPRIDONE ONC201 IN COMBINATION WITH THE ONCOLYTIC ADENOVIRUS DELTA-24-RGD HAS A SYNERGISTIC EFFECT IN PRECLINICAL MODELS OF PHGGS AND DMGS
por: de la Nava, Daniel, et al.
Publicado: (2021)

HGG-50. TWO CASES OF H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA OF CERVICAL SPINAL CORD
por: Kuroha, Masae, et al.
Publicado: (2020)

HGG-38. DE NOVO PYRIMIDINE SYNTHESIS INHIBITION INDUCES REPLICATION CATASTROPHE MEDIATED CELL DEATH IN DIFFUSE MIDLINE GLIOMA
por: Pal, Sharmistha, et al.
Publicado: (2021)

HGG-03. THE GLYCOSPHINGOLIPIDS METABOLISM IS A NOVEL TARGET IN H3K27M-MUTANT DIFFUSE MIDLINE GLIOMA
por: Paret, Claudia, et al.
Publicado: (2021)

HGG-14. ACT001 – A PROMISING THERAPEUTIC FOR DIFFUSE INTRINSIC PONTINE GLIOMAS
por: Upton, Dannielle, et al.
Publicado: (2021)

HGG-33. Prognostic factors of H3K27M histone-mutant diffuse midline gliomas in patients ≤18yrs
por: Hu, Qingjun, et al.
Publicado: (2022)

HGG-31. Unique case of a bithalamic H3K27-wildtype diffuse midline glioma, EGFR-altered with methylated MGMT
por: Reinecke, James, et al.
Publicado: (2022)

HGG-39. ALTERNATIVE SPLICING OF NEUROFIBROMIN 1 IS ASSOCIATED WITH ELEVATED MAPK ACTIVITY AND POOR PROGNOSIS IN HIGH-GRADE GLIOMA
por: Siddaway, Robert, et al.
Publicado: (2021)

DIPG-22. TRIPTOLIDE AS A POTENTIALLY PROMISING THERAPY FOR DIFFUSE MIDLINE GLIOMA
por: Ciani, Ludovica, et al.
Publicado: (2023)

HGG-44. DEFECTS OF MISMATCH REPAIR PROTEINS IN PEDIATRIC HIGH GRADE GLIOMAS
por: Haberler, Christine, et al.
Publicado: (2020)

HGG-35. IDENTIFICATION OF G PROTEIN-COUPLED RECEPTOR 17 (GPR17) UP-REGULATION IN PAEDIATRIC H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA AND EXAMINATION OF ITS ROLE IN DIFFUSE MIDLINE GLIOMA CELL LINES
por: Loveson, Katie, et al.
Publicado: (2021)

HGG-36. ONC201 TARGETING IN DIPG
por: Abuarqoub, Alqassem, et al.
Publicado: (2021)

HGG-29. How I treat recurrent pediatric high-grade glioma (HGG): A Europe-wide survey study.
por: Perwein, Thomas, et al.
Publicado: (2022)

HGG-58. SIOPE HGG Working Group approach to obtain consensus on management of paediatric high grade glioma across Europe
por: Giraud, Géraldine, et al.
Publicado: (2022)

HGG-31. UNIQUE BIOLOGICAL CHARACTERISTICS OF RADIATION-INDUCED GLIOMAS
por: Váňová, Kateřina, et al.
Publicado: (2020)

HGG-44. REVEALING VULNERABILITIES IN DIPG THROUGH ONC201
por: Stafford, James, et al.
Publicado: (2021)

HGG-33. EXPLOITING METABOLIC DEFECTS WITH NAMPT INHIBITORS IN DIPG
por: Muraleedharan, Ranjithmenon, et al.
Publicado: (2021)

HGG-09. FIRST LINE THERAPY OF PEDIATRIC GLIOBLASTOMA WITH LAROTRECTINIB
por: Alharbi, Musa, et al.
Publicado: (2020)

HGG-39. CLINICAL CHARACTERISTICS AND OUTCOME OF PATIENTS WITH RADIATION-INDUCED GLIOMA
por: Ohno, Makoto, et al.
Publicado: (2020)

HGG-21. MALIGNANT SYNAPTIC PLASTICITY IN PEDIATRIC HIGH-GRADE GLIOMAS
por: Taylor, Kathryn, et al.
Publicado: (2021)

HGG-32. UNCOVERING THERAPEUTIC VULNERABILITIES IN MISMATCH REPAIR-DEFICIENT GLIOMAS
por: Boynton, Adam, et al.
Publicado: (2020)

HGG-41. STRUCTURAL VARIANT DRIVERS IN PEDIATRIC HIGH-GRADE GLIOMA
por: Dubois, Frank, et al.
Publicado: (2020)

HGG-56. Spatial mapping of the tumor micro-environment in pediatric glioma
por: Messiaen, Julie, et al.
Publicado: (2022)

HGG-51. Uncovering therapeutic vulnerabilities in mismatch repair-deficient gliomas
por: Boynton, Adam, et al.
Publicado: (2022)

HGG-22. Uptake of investigational therapy in children with High Grade Glioma
por: Toledano, Helen, et al.
Publicado: (2022)

HGG-48. ROS1 INHIBITOR ENTRECTINIB USE IN RELAPSE/REFRACTORY INFANTILE GLIOBLASTOMA WITH POSITIVE ROS1 FUSION - A CASE REPORT WITH PROMISING RESPONSE
por: Ku, Dennis Tak-Loi, et al.
Publicado: (2020)

HGG-34. DETECTION OF ONCOGENIC FUSION EVENTS IN SUPRATENTORIAL GLIOBLASTOMAS OF YOUNG CHILDREN
por: Pietsch, Torsten, et al.
Publicado: (2020)

HGG-42. CLINICAL FEATURES AND TREATMENT OUTCOME OF MALIGNANT GLIOMAS IN CHILDREN AND ADOLESCENTS
por: Yonezawa, Hajime, et al.
Publicado: (2020)

HGG-16. EXOSOME-MEDIATED INTER-CLONAL INTERACTIONS IN PEDIATRIC GBM AND DIPG
por: Pericoli, Giulia, et al.
Publicado: (2020)

HGG-41. CHARACTERIZATION OF THE IMMUNE RESPONSE FOLLOWING VARIOUS RADIOTHERAPY TREATMENTS IN GLIOBLASTOMA
por: Cocito, Carolina, et al.
Publicado: (2021)

HGG-24. NTRK-rearranged infantile gliomas of suprasellar/ optic pathway origin
por: Lazow, Margot A, et al.
Publicado: (2022)

HGG-40. NF1 mosaicism in a CMMRD-patient with a glioblastoma
por: Guerrini-Rousseau, Lea, et al.
Publicado: (2022)

HGG-17. Novel Fusion in Congenital Brainstem Diffuse High-Grade Glioma
por: Norris, Gregory, et al.
Publicado: (2022)

DIPG-64. INTERNATIONAL PRECLINICAL DRUG DISCOVERY AND BIOMARKER PROGRAM INFORMING AN ADOPTIVE COMBINATORIAL TRIAL FOR DIFFUSE MIDLINE GLIOMAS
por: Przystal*, Justyna M, et al.
Publicado: (2020)

HGG-27. ANTI-CANCER POTENTIAL OF ARGINASE FOR HIGH-GRADE GLIOMA IN VITRO & IN-VIVO
por: Fung, M K L, et al.
Publicado: (2020)

HGG-22. EVALUATING THE REGULATION OF BLOOD-BRAIN BARRIER INTEGRITY IN DIPG MOUSE MODELS
por: Wei, Xin, et al.
Publicado: (2021)

HGG-27. HNRNPA1 SPLICED VARIANT SENSITIZATION EFFECT DISCLOSED IN GLIOMA CELLS
por: Yadav, Ajay
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_atvumrdp3osurc7oegmqh06s19